MS-01DEVELOPMENT OF MALIGNANT PERIPHERAL NERVE TUMOR MODEL FOR EVALUATING A TUMOR TARGETED LIPOSOME-BASED THERAPY

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2014-11, Vol.16 (Suppl 5), p.v127-v127
• Main Authors: Achutha, Madhankumar, Slagle-Webb, Becky, Rizk, Elias, Payne, Russell, Harbaugh, Kimberly, Connor, James
• Format: Article
• Language: English
• Subjects: Abstracts
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/nou260.1

In our previous studies we demonstrated the expression of IL-13Rα2 receptor in several malignant and benign peripheral nerve sheath tumors. In a subsequent study we investigated the specific binding of the IL-13 conjugated liposomal doxorubicin (IL13LIPDXR) to the MPNST cells and their cytotoxic property in the monolayer and spheroid model. To demonstrate the in vivo therapeutic efficacy, a sciatic nerve tumor model was developed in nude mice using STS26T, a MPNST cell line. The STS26T cell line was stably transfected with a luciferase expressing plasmid using a nanoliposome technology developed in our laboratory. These luciferase transfected cells were injected in the sciatic nerve in NIH III nude mice and allowed to grow for 2-4 weeks. To confirm the tumor formation intravital imaging spectroscopy (IVIS) and MR imaging were performed after injection of luciferin-D, a substrate for the luciferase. For our pathological studies, the mice were sacrificed and the tumor along with the nerve was dissected and paraffin embedded. The tumor was sectioned and the sections were subjected to immunohistochemistry (IHC) for the presence of IL-13Rα2 receptor protein, ki-67 a cell proliferation marker, heavy chain ferritin and S100 (myelin forming Schwann cells). Our experiment demonstrated the presence of IL-13R2 receptor, ki-67, H-ferritin and S100 at variable levels in the tumor. Experiments are in progress to develop an effective therapeutic strategy using IL-13 targeted liposomes.